Bharat Parenterals FY26 Results: Dividend, Loss Narrowing

• Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, with unmodified audit opinions.
• Recommended final dividend of ₹1.00 per equity share (10%) for FY26, subject to shareholder approval at AGM.
• Re-appointed Chetan Gandhi & Associates as Cost Auditor and Dhruvik Parikh & Co. as Internal Auditor for FY2026-27.
• Consolidated FY26 revenue flat at ₹345.4 crore while EBITDA improved to ₹15.8 crore and PAT loss narrowed to ₹(27.3) crore.